November 2018 Issue Table Of Contents

From The Editor

• When One Door Closes…

Feature Articles

• Liz Barrett — Novartis Oncology’s NextGen Leader
• Lysogene: Mother of Invention
• ARM Extends Its Reach

Capitol Perspectives

• Told You So! Repeal Of Individual Mandate Penalty Has No Impact

Patient Perspectives

• Chronic Disease Management And The Need For Control

From Principles and Policy to Execution

• Improving Access To Care Via Asset-Light Approaches  

Industry Research

• The Interconnected World Of Blockbuster Oncology Drugs

Companies To Watch

• Athersys

Inside The Industry

• Decision-making Responsibilities When Outsourcing Late-Phase Studies
• How To Put A Price Tag On Emerging Therapies
• A Small Biotech Takes On Some Big Clinical Trial Challenges
• Why A State Of Agility Continues To Elude Life Sciences R&D
• How The Regulatory Pathway Shapes Biosimilar Business Decisions
• MD’s I270 Biotech Corridor: A Hub Within A Hub
• Why Biopharma Startups Need Organizational Effectiveness
• EU Drug Safety Through FMD Serialization Readiness
• Biopharma Bringing RWE Into The Real World

Leadership Lessons

• Mastering The Flow Of Talent

Ask The Board

• What Advice Do You Have For Companies On Building The Science Of Patient Input Into Clinical Trial Development And Execution?
• Are The Economics Of Healthcare Delivery Consistent With Classic Theories Of Supply And Demand? It Seems Not When Consumers Are Not The Payers.
• To What Extent Do You Believe That The Combination Of Quality/Relevance Of Products (Or Service), Corporate Culture, And Corporate Values Drives The Successful Integration Of A Company Following A Merger?